Company / Operating Cash Flow
Processa Pharmaceuticals, Inc. Operating Cash Flow History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$8.7M
FY2022
5-year range
-$8.7M / -$871.9K
FY2018-FY2022
Trend
-177.3%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$871,906 to -$9M over the past 6 years.
Based on SEC 10-K filings.
-$9M in FY2022.
Declined from -$871,906 to -$9M over the past 6 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating cash flow decreased 177.3% year-over-year.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$8.7M | -177.3% |
| FY2021 | -$3.1M | -260.5% |
| FY2016 | -$871.9K | +67.6% |
| FY2015 | -$2.7M | -6.0% |
| FY2014 | -$2.5M | -34.1% |
| FY2013 | -$1.9M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026